Search

United Therapeutics Corp

Open

BrancheGesundheitswesen

516.17 -1.6

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

508.46

Max

530.88

Schlüsselkennzahlen

By Trading Economics

Einkommen

58M

333M

Verkäufe

1.8M

783M

KGV

Branchendurchschnitt

18.206

57.366

EPS

7.27

Gewinnspanne

42.512

Angestellte

1,400

EBITDA

32M

376M

Empfehlungen

By TipRanks

Empfehlungen

Starkes Kaufsignal

12-Monats-Prognose

+26.8% upside

Dividenden

By Acuity

Nächstes Ergebnis

28. Okt. 2026

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

-3.9B

22B

Vorheriger Eröffnungskurs

517.77

Vorheriger Schlusskurs

516.17

Nachrichtenstimmung

By Acuity

31%

69%

99 / 340 Ranking in Healthcare

United Therapeutics Corp Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

26. Aug. 2026, 19:46 UTC

News

United Therapeutics shares are lower as CEO Martine Rothblatt exercised an option for 9,500 shares at $135.42, raising potential supply concerns.

25. Aug. 2026, 23:26 UTC

United Therapeutics Corp. shares are trading roughly flat in after-market hours, reflecting routine performance and remaining near the middle of their one-month trading range.

24. Aug. 2026, 21:01 UTC

Event

United Therapeutics shares lower in after-market hours following FDA acceptance of ralinepag's New Drug Application for pulmonary arterial hypertension.

21. Aug. 2026, 19:46 UTC

News

United Therapeutics Corp shares are lower amid rising U.S. Treasury yields, which have heightened concerns about inflation and government debt levels.

20. Aug. 2026, 23:16 UTC

Shares of United Therapeutics Corp are trading higher in after-market hours, despite routine fluctuations and a decrease from an earlier high.

19. Aug. 2026, 22:02 UTC

United Therapeutics Corp. shares declined in after-market trading, reversing gains from the previous three sessions. No specific news was identified to explain the drop.

18. Aug. 2026, 19:11 UTC

Event
News

United Therapeutics shares are higher, supported by insider activity and full enrollment in the TETON-PPF study evaluating Tyvaso for pulmonary fibrosis.

17. Aug. 2026, 19:46 UTC

News
Social Media
Event

United Therapeutics Corp completed enrollment in its Phase 3 TETON-PPF study for Tyvaso, and shares are advancing during Monday's session, despite a pullback earlier.

13. Aug. 2026, 19:51 UTC

United Therapeutics Corp shares are lower today, breaking a trend of higher closes. No specific news was identified to explain the decline.

12. Aug. 2026, 23:01 UTC

United Therapeutics Corp shares are higher in after-market trading, supported by easing concerns over Federal Reserve rate hikes amid rising consumer prices.

11. Aug. 2026, 23:02 UTC

United Therapeutics Corp is trading lower in after-market hours, continuing a trend of three consecutive daily declines without any specific news driving the movement.

10. Aug. 2026, 20:06 UTC

United Therapeutics Corp shares are lower during Monday's session, with no specific news identified to explain the decline amid broader market volatility.

7. Aug. 2026, 19:51 UTC

Social Media
News

United Therapeutics Corp shares are higher, driven by positive sentiment from significant insider transactions and strong investor interest amid a rising Biotechnology sector.

6. Aug. 2026, 23:01 UTC

United Therapeutics Corp. shares are higher in after-market trading, continuing a steady increase since Thursday's close and remaining above the 20-day moving average.

5. Aug. 2026, 20:02 UTC

News
Social Media

United Therapeutics reported second-quarter revenues of $783.3 million, missing estimates of $805.6 million, while EPS of $7.27 exceeded expectations by $0.18.

4. Aug. 2026, 23:51 UTC

Shares of United Therapeutics Corp. are lower in after-market hours, remaining below the 20-day moving average and near the lower end of their one-month trading range.

3. Aug. 2026, 19:16 UTC

Shares of United Therapeutics Corp are lower today, trading near the lower end of their one-month range amid a broader market rally in other sectors.

30. Juli 2026, 14:36 UTC

Event

United Therapeutics shares are higher following the publication of full ADVANCE OUTCOMES study results in The Lancet, pending FDA approval for ralinepag.

29. Juli 2026, 20:51 UTC

Event

United Therapeutics shares are higher in after-market trading following The Lancet's publication of results from the ADVANCE OUTCOMES study on Ralinepag for PAH.

28. Juli 2026, 18:21 UTC

United Therapeutics Corp. shares are lower today, continuing a decline since Monday's close amid broader market trends and three consecutive sessions of lower finishes.

24. Juli 2026, 16:36 UTC

News
Social Media

United Therapeutics appointed Victor Dzau to its Board of Directors, enhancing its strategic direction. Shares are modestly higher since Thursday's close.

22. Juli 2026, 19:41 UTC

News

United Therapeutics filed an $833.4 million shelf registration for 1.5 million shares, contributing to downward pressure on shares amid broader market movements.

21. Juli 2026, 16:56 UTC

United Therapeutics Corp is seeing modest gains today, with positive sentiment from Asian markets contributing to overall investor optimism. No specific news was identified.

Peer-Vergleich

Kursveränderung

United Therapeutics Corp Prognose

Kursziel

By TipRanks

26.8% Vorteil

12-Monats-Prognose

Durchschnitt 655.13 USD  26.8%

Hoch 714 USD

Tief 515 USD

Basierend auf 9 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für United Therapeutics Corp – Dist angeboten haben.

Rating-Konsens

By TipRanks

Starkes Kaufsignal

9 ratings

7

Buy

2

Halten

0

Sell

Stimmung

By Acuity

99 / 340 Ranking in Gesundheitswesen

Nachrichtenstimmung

Bullische Evidenz

Volatilität

Unterdurchschnittlich

Nachrichtenvolumen (RCV)

Überdurchschnittlich

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über United Therapeutics Corp

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for treating high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin. In addition, the company engages in developing RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and Nebulized Tyvaso, for the treatment of idiopathic pulmonary fibrosis, as well as xenografts, which are development-stage organ products. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland.
help-icon Live chat